Akashi Therapeutics Receives Fast Track Designation For HT-100 From FDA For The Treatment Of Duchenne Muscular Dystrophy
7/3/2014 6:05:25 AM
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Akashi Therapeutics, Inc., announced today that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to the company’s most advanced product candidate, HT-100 (delayed-release halofuginone), an orally available, small molecule drug candidate intended to reduce fibrosis and inflammation and promote healthy muscle regeneration in boys with DMD. Fast track designation is granted by the FDA to facilitate the development and expedite the review of new drugs that are intended to treat serious or life-threatening conditions and that demonstrate the potential to address unmet medical needs.
Help employers find you! Check out all the jobs and post your resume.
comments powered by